PAUL LASZLO BOLLYKY
Osteopathic Medicine in Seattle, WA
License number
Washington MD00043880
Category
Osteopathic Medicine
Type
Hospice and Palliative Medicine
License number
Washington C56109
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
1019 N49 St, Seattle, WA 98103
Phone
(206) 634-9183
Personal information
See more information about PAUL LASZLO BOLLYKY at radaris.comName
Address
Phone
1019 N 49Th St, Seattle, WA 98103
1019 49Th St, Seattle, WA 98103
Professional information
Dr. Paul L Bollyky, Seattle WA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
325 9Th Ave, Seattle 98104
(206) 744-3000 (Phone)
(206) 744-3000 (Phone)
Certifications:
Infectious Disease, 2007, Internal Medicine, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
325 9Th Ave, Seattle 98104
Harborview Medical Center
325 9Th Ave, Seattle 98104
Harborview Medical Center
325 9Th Ave, Seattle 98104
Education:
Medical School
Harvard Medical School
Graduated: 2001
Harvard Medical School
Graduated: 2001
Paul Laszlo Bollyky, Seattle WA
Specialties:
Internist
Address:
4 Uw Health Sciences Anx, Seattle, WA 98195
Compositions And Methods For Treating Airway Inflammatory Diseases
US Patent:
2012032, Dec 20, 2012
Filed:
Jun 14, 2012
Appl. No.:
13/523736
Inventors:
Paul Bollyky - Seattle WA, US
Gerald T. Nepom - Lopez WA, US
Michael G. Kinsella - Seattle WA, US
Gerald T. Nepom - Lopez WA, US
Michael G. Kinsella - Seattle WA, US
Assignee:
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON - Seattle WA
International Classification:
A61K 39/35, A61P 11/06, A61K 39/36, A61P 11/08, A61P 11/04, A61P 11/00, A61P 37/08
US Classification:
4242751
Abstract:
A composition for treating an airway inflammatory disease having high molecular weight, crosslinked hyaluronan and at least one aeroallergen is provided. A method of inducing immune tolerance to one or more aeroallergens in a mammalian subject suffering from or at risk of developing an airway inflammatory disease, and a method of treating a human subject suffering from or at risk of developing an airway inflammatory disease or condition of the lungs are also provided.